✦ LIBER ✦

Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?

✍ Scribed by Dillman, Robert O; Cornforth, Andrew N; Nistor, Gabriel

Book ID: 120201754
Publisher: Informa plc
Year: 2013
Tongue: English
Weight: 477 KB
Volume: 13
Category: Article
ISSN: 5847-4714
DOI: 10.1517/14712598.2013.759556

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stem Cells and Cancer Stem Cells, Volume

Stem Cells and Cancer Stem Cells, Volume 9 || Cancer Stem Cell Antigens from Autologous Tumor Cell Lines in Patient-Specific Active Immunotherapy for Metastatic Cancer

✍ Hayat, M.A. 📂 Article 📅 2012 🏛 Springer Netherlands 🌐 Dutch ⚖ 269 KB

This fresh addition to the rapidly expanding Springer series on stem cells represents an additional forward step in our understanding of the causes, diagnosis, and cell-related therapies of major human diseases as well as debilitating injuries to human tissue and organs. Showcasing the work of more

Immunotherapy of cancer by peptide-based

Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity

✍ Maaike E Ressing; Rienk Offringa; RenéE.M Toes; Ferry Ossendorp; Joan H de Jong; 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 887 KB

Hematopoietic stem cells and progenitors

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy

✍ Yong, A S M; Keyvanfar, K; Eniafe, R; Savani, B N; Rezvani, K; Sloand, E M; Gold 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 575 KB

Phase I Study of the BLP25 (MUC1 Peptide

Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer

✍ Martin Palmer; Joanne Parker; Shanu Modi; Charlie Butts; Mike Smylie; Allison Me 📂 Article 📅 2001 🏛 CIG Media Group, LP. 🌐 English ⚖ 423 KB

Commentary on “Phase I Study of the BLP2

Commentary on “Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer”

✍ Kathy Schiffman; Mary L. Disis 📂 Article 📅 2001 🏛 CIG Media Group, LP. 🌐 English ⚖ 53 KB